Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors.

Agios Pharmaceuticals, Inc. rose 3.64% intraday, with the company announcing the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. His extensive leadership experience and strategic business acumen are expected to benefit Agios as it continues to develop transformative therapies for patients living with rare diseases.